Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

GlobeNewswire March 6, 2018

REGENXBIO, Inc. to Host Earnings Call

Accesswire March 6, 2018

Regenxbio Q4 Earnings Outlook

Benzinga.com  March 6, 2018

REGENXBIO to Host Conference Call on March 6 to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights

GlobeNewswire February 27, 2018

REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

GlobeNewswire February 8, 2018

REGENXBIO to Participate in Upcoming Investor Conferences

GlobeNewswire February 7, 2018

REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into Strategic Partnership with FUJIFILM Diosynth Biotechnologies

GlobeNewswire January 23, 2018

REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy

GlobeNewswire January 8, 2018

8 Stocks Moving In Thursday's After-Hours Session

Benzinga.com  January 4, 2018

REGENXBIO Provides Year-End 2017 Corporate Update

GlobeNewswire January 4, 2018

REGENXBIO Announces IND Active for Phase I/II Trial of RGX-121 to Treat Mucopolysaccharidosis Type II

GlobeNewswire December 19, 2017

REGENXBIO to Present at Upcoming Investor Conferences

GlobeNewswire November 22, 2017

REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights

GlobeNewswire November 8, 2017

REGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2017 Financial Results and Recent Operational Highlights

GlobeNewswire November 1, 2017

Ultragenyx to Acquire Dimension Therapeutics

GlobeNewswire October 3, 2017

REGENXBIO to Present at Upcoming Investor Conferences

GlobeNewswire October 3, 2017

REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics

GlobeNewswire October 2, 2017

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”

GlobeNewswire October 2, 2017

REGENXBIO Announces Completion of Dosing of First Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD

GlobeNewswire September 20, 2017

Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”

GlobeNewswire September 19, 2017